Informatie:
Fout:
ID
34393
Beschrijving
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01283386
Link
https://clinicaltrials.gov/show/NCT01283386
Trefwoorden
Versies (1)
- 17-01-19 17-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
- StudyEvent: Eligibility
Similar models
Eligibility Lymphocytic Leukemia, Chronic NCT01283386
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
adult patients, 60-70 or >70 years of age
boolean
ID.2
Item
cumulative illness rating scale (cirs) comorbidity score >/=7 if patient is 60-70 years old
boolean
ID.3
Item
previously untreated b-cell chronic lymphocytic leukemia
boolean
ID.4
Item
binet stage b, c or a with progression
boolean
ID.5
Item
ecog performance status 0-2
boolean
ID.6
Item
small-cell lymphoma
boolean
ID.7
Item
autoimmune hemolytic anemia
boolean
ID.8
Item
concomitant malignant disease during enrollment, except for basal cell carcinoma of the skin
boolean
ID.9
Item
chemotherapy for concomitant malignant disease within 12 months prior to study enrollment
boolean
ID.10
Item
richter's syndrome
boolean